WILMINGTON, DE & WHIPPANY, NJ — The Noramco Group has announced a $25 million investment to expand its Halo Pharma facility in Whippany, New Jersey, by adding sterile injectable manufacturing capabilities. This initiative aims to alleviate critical shortages in the U.S. injectable supply chain while meeting growing demand for domestic production.
The expansion will introduce a state-of-the-art Groninger UFVN FlexFill syringe, cartridge, and vial filling line along with a SKAN isolator to ensure efficiency and regulatory compliance. The facility will be equipped to produce batches ranging from 5,000 to 250,000 units, with an annual capacity exceeding 50 million units. Initial container systems will include ready-to-fill formats for 0.5 mL, 1 mL long, 1 mL short syringes, and 2R vials, with additional options available as demand grows.
“This investment is a significant step in our commitment to build on our position as one of the only fully integrated domestic supply options for our customers,” said Lee Karras, CEO of The Noramco Group. “We recognize the challenges facing the industry and are dedicated to providing solutions that address both immediate and long-term supply chain needs. While enhancing our technology and capacity, we remain steadfast in continuing our established roles in manufacturing APIs, oral solid doses, and liquid dosage forms.”
With sterile injectables now the fastest-growing segment of the pharmaceutical market, demand continues to exceed production capacity, often contributing to shortages of critical drugs. This new investment reinforces The Noramco Group’s commitment to providing reliable sterile injectable manufacturing in North America, ensuring greater supply chain security for both branded and generic products.
The Whippany facility, with its 20-year history in oral solid dose, semi-solid, and liquid formulations, will undergo extensive renovations to integrate the new technology while retaining its original capabilities. Upgrades will also include enhancements to meet EU Annex 1 compliance, positioning the facility to serve both U.S. and European markets.
“We anticipate the new line to be qualified and operational within the next 12 months,” added Karras. “This ensures we are well-positioned to support our customers with high-quality sterile injectable products, addressing shifting industry needs to maintain a stable and secure supply chain.”
Through this investment, The Noramco Group aims to address a critical gap in the U.S. pharmaceutical landscape, paving the way for enhanced production capacity and heightened supply chain reliability in the growing sterile injectables market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.